Amrutanjan Health Care Ltd
Amrutanjan Health Care Q4 FY25 earnings call: Revenue & Margins
Q4 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹135Cr
- +6.3% YoY
- Net profit
- ₹15Cr
- +7.1% YoY
- Margin
- 13%
- 0 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Amrutanjan Health Care Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY25 Net Sales: Rs. 135.41 Cr, up 6.57% YoY (Q4 FY24: Rs. 127.06 Cr). For Q4 FY25:.
From Amrutanjan Health Care Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4 FY25 Net Sales: Rs. 135.41 Cr, up 6.57% YoY (Q4 FY24: Rs. 127.06 Cr)
- Q4 FY25 Profit Before Tax: Rs. 20.86 Cr, up 6.43% YoY (Q4 FY24: Rs. 19.60 Cr)
- Q4 FY25 Profit After Tax: Rs. 15.18 Cr, up 11.13% YoY (Q4 FY24: Rs. 13.66 Cr)
- Q4 FY25 OTC Net Sales (including Comfy): Rs. 117.24 Cr, up 13.84% YoY (Q4 FY24: Rs. 108.37 Cr)
- Q4 FY25 Comfy Net Sales: Rs. 34.46 Cr, up 8.18% YoY (Q4 FY24: Rs. 30.27 Cr)
- Q4 FY25 Beverages Net Sales: Rs. 17.67 Cr, up 0.37% YoY (Q4 FY24: Rs. 18.67 Cr)
- Q4 FY25 Electro Plus Net Sales: Rs. 16.20 Cr, up 0.37% YoY (Q4 FY24: Rs. 16.14 Cr)
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Amrutanjan Health Care Ltd Q4 FY25 results — key figures
| ₹ Cr | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 135 | 127 | +6.3% | 123 | +9.8% |
| Operating profit (EBITDA) | 18 | 16 | +12.5% | 23 | -21.7% |
| Operating margin | 13% | 13% | 0 pp | 19% | -6 pp |
| Profit before tax | 21 | 20 | +5% | 26 | -19.2% |
| Net profit (PAT) | 15 | 14 | +7.1% | 19 | -21.1% |
| EPS (₹) | 5.25 | 4.72 | +11.2% | 6.66 | -21.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Jubilant Pharmo (Q4 FY25)
Q4 FY25 consolidated revenue grew 10% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q4 FY25 earnings call — and how it ranks against sector…
- Anuh Pharma (Q4 FY25)
For Q4 FY 2025, operating revenue was ₹198.14 crore, a 2.24% year-on-year increase from ₹193.63 crore in Q4 FY 2024 (derived from annual total revenue…
- Themis Medicare (Q4 FY25)
71.70 Cr, down 27% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
- Lincoln Pharmaceuticals (Q4 FY25)
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q4 FY25 results?
Q4 FY25 Net Sales: Rs. 135.41 Cr, up 6.57% YoY (Q4 FY24: Rs. 127.06 Cr). For Q4 FY25:.
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.